Neoadjuvant Immunotherapy Represents an Improved Option for Resectable Melanoma
Anna Pavlick, DO, MBA, discusses key updates from clinical trials that continue to shape the treatment of patients with melanoma, the role of immunotherapy in the frontline setting, and the importance of toxicity management and patient support.
Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
October 31st 2022Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents to treat solid tumors, and the challenges of investigating rare cancers.
A Newly Identified Genetic Mutation May Be Key to Developing Thymic Cancer Treatment
Recent developments in cancers of the thymus, a small organ located in the mediastinum above the heart, have shined a light on a malignancy that only affects about 400 Americans annually.
Women in Oncology: Bringing Advances From the Lab Into the Clinic
August 19th 2022Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.
Women in Oncology: How Early Treatments Paved the Way for Future Advances
August 18th 2022Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.
Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL
August 17th 2022Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.
Two Fellows Use Online Resources to Boost Genetic Testing
April 16th 2022Widespread germline testing in the United States could prevent cancer in hundreds of thousands of people. However, despite known benefits, uptake for genetic testing has been slow: only 1 in 5 individuals use recommended genetic services even when there is a significant family history of colorectal, breast, or ovarian cancer.